Passage Bio Inc (PASG) Reports Q2 2022 Financial Results
Passage Bio Inc (PASG) announced its financial results for the period ending Q2 2022.
Key Financial Highlights:
Revenue: Not disclosed
Net Income: Not disclosed
EPS: Not disclosed
Cash and equivalents: 101614
1 clinical trial for GM1 gangliosidosis; interim safety and biomarker data for both cohorts expected in 2H22●Dosed first patient in Cohort 1 in GALax
C clinical trial in infantile Krabbe disease; interim safety and biomarker data expected by year
end 2022●Submitted IND for Phase 1/2 clinical program of PBML04 for metachromatic leukodystrophy●Completed strategic prioritization to extend cash runway into 2Q24●Management to host conference call today at 8:30 a.m. ETPhiladelphia, PA – May 16, 2022 – Passage Bio, Inc. (Nasdaq: PASG), a clinical
expected in 2H22●Dosed first patient in Cohort 1 in GALax-C clinical trial in infantile Krabbe disease; interim safety and biomarker data expected by year-end 2022
📋 PASSAGE BIO, INC. (PASG) - Financial Results
Filing Date: 2022-05-16
Accepted: 2022-05-16 07:15:42
Event Type: Financial Results
Event Details:
📊 Key Financial Metrics (Year-over-Year Comparison):
💼 Business Developments:
Structured Data: